Search
Make Good Use of Your Sidebar

Use this space for anything from simple blocks of text to powerful widgets, like our Twitter and Flickr widgets. Learn more.

To access Website Management, hit the 'esc' key or use this Login link.

Blog Index
The journal that this archive was targeting has been deleted. Please update your configuration.
Navigation

Developing First-in-Class, Precision-Targeted Therapies for Cancer based on based on the Photoimmunotherapy platform

Aspyrian Therapeutics Inc (San Diego, USA), is developing a new class of precision oncologic drugs for the treatment of solid tumors based on the Photoimmunotherapy platform licensed exclusively from the National Cancer Institute (NCI, USA). For additional information please contact us.

Photoimmunotherapy (PIT) utilizes cancer-selective antibodies conjugated to the molecule IRDye® 700DX that is activated with a laser at the tumor site to induce rapid cancer cell destruction. The dual targeting resulting from in-tumor activation of a tumor-selective conjugate promises to deliver oncologists the ability to achieve locoregional tumor control with minimal damage to surrounding healthy tissues and structures. Importantly, laser activation can be accomplished on an outpatient basis by either external illumination or by needle placement of an optical fiber to illuminate a deep-seated tumor from within.  Aspyrian Therapeutics Inc. has secured the exclusive license to use IRDye® 700DX from Li-COR (Lincoln, Nebraska) for development of Photoimmunotherapy products. The Company is currently working with a number of monoclonal antibodies with the potential to treat various types of cancers, including head and neck, esophageal, lung, brain, pancreatic, colorectal, breast and ovarian.